生物相容性腹膜透析液在终末期肾病中应用的进展_West China Medical Journal

Authors：

蔡盼盼 , 李孜 ,  唐晓红

四川大学华西医院肾脏内科（成都 610041）;

Corresponding author：

唐晓红, Email: xhtng@126.com

Keywords：

腹膜透析; 终末期肾病; 生物相容性腹膜透析液

DOI：

10.7507/1002-0179.201505176

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

腹膜透析（腹透）是终末期肾病患者肾脏替代治疗的有效方式之一，但传统腹透液的生物不相容性使腹透寿命受到限制。有研究发现，生物相容性腹透液对终末期肾病患者的影响优于传统腹透液。该文就生物相容性腹透液对终末期肾病患者残余肾功能、腹膜功能、腹膜炎发生率、技术失败、全因死亡等方面影响的研究进展进行了综述。

Citation： 蔡盼盼, 李孜, 唐晓红. 生物相容性腹膜透析液在终末期肾病中应用的进展. West China Medical Journal, 2017, 32(4): 626-629. doi: 10.7507/1002-0179.201505176 Copy

1.	Devuyst O, Margetts PJ, Topley N. The pathophysiology of the peritoneal membrane. J Am Soc Nephrol, 2010, 21(7): 1077-1085.
2.	Topley N. Membrane longevity in peritoneal dialysis: impact of infection and bio-incompatible solutions. Adv Ren Replace Ther, 1998, 5(3): 179-184.
3.	Witowski J, Jörres A. Effects of peritoneal dialysis solutions on the peritoneal membrane: clinical Consequences. Perit Dial Int, 2005, 25(Suppl 3): S31-S34.
4.	Pecoits-Filho R, Stenvinkel P, Heimburger O, et al. Beyond the membrane-the role of new PD solutions in enhancing global biocompatibility, Kidney Int Suppl, 2003, 2003(88): S124-S132.
5.	Nau B, Schmitt CP, Almeida M, et al. BIOKID: randomized controlled trial comparing bicarbonate and lactate buffer in biocompatible peritoneal dialysis solutions in children, BMC Nephrol, 2004, 2004(5): 14.
6.	Haag-Weber M, Krämer R, Haake R, et al. Low-GDP fluid (Gambrosol trio) attenuates decline of residual renal function in PD patients: a prospective randomized study. Nephrol Dial Transplant, 2010, 25(7): 2288-2296.
7.	Brown F, Johnson DW. A randomized controlled trial to determine whether treatment with at neutral pH, low glucose degradation product dialysate (balance) prolongs residual renal function in peritoneal dialysis patients. Perit Dial Int, 2006, 26(1): 112-113; author reply 114.
8.	Johnson DW, Brown FG, Clarke M, et al. Effects of biocompatibleversus standard fluid on peritoneal dialysis outcomes. J Am Soc Nephrol, 2012, 23(6): 1097-1107.
9.	Johnson DW, Clarke M, Wilson V, et al. Rationale and design of the balANZ trial: a randomized controlled trial of low GDP, neutral pHversus standard peritoneal dialysis solution for the preservation of residual renal function, BMC Nephrol, 2010, 2010(11): 25.
10.	Johnson DW, Brown FG, Clarke M, et al. The effect of low glucose degradation product, neutral pHversus standard peritoneal dialysis solutions on peritoneal membrane function: the balANZ trial. Nephrol Dial Transplant, 2012, 27(12): 4445-4453.
11.	Cho Y, Johnson DW, Craig JC, et al. Biocompatible dialysis fluids for peritoneal dialysis. Cochrane Database of Systematic Reviews, 2014, 27(3): CD007554.
12.	Seo EY, An SH, Cho JH, et al. Effect of biocompatible peritoneal dialysis solution on residual renal function: a systematic review of randomized controlled trials. Perit Dial Int, 2014, 34(7): 724-731.
13.	Rippe B, Wieslander A, Musi B. Long-term results with low glucose degradation product content in peritoneal dialysis fluids. Contrib Nephrol, 2003(140): 47-55.
14.	Choi HY, Kim DK, Lee TH, et al. The clinical usefulness of peritoneal dialysis fluids with neutral pH and low glucose degradation product concentration: an open randomized prospective trial. Perit Dial Int, 2008, 28(2): 174-182.
15.	Williams JD, Topley N, Craig KJ, et al. Euro Balance Trial Group. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int, 2004, 66(1): 408-418.
16.	Szeto CC, Chow KM, Lam CW, et al. Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products--a 1-year randomized control trial. Nephrol Dial Transplant, 2007, 22(2): 552-559.
17.	Fried LF, Bernardini J, Johnston JR, et al. Peritonitis influences mortality in peritoneal dialysis patients. J Am Soc Nephrol, 1996, 7(10): 2176-2182.
18.	Davies SJ, Bryan J, Phillips L, et al. Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis. Nephrol Dial Transplant, 1996, 11(3): 498-506.
19.	Kawanishi H, Watanabe H, Moriishi M, et al. Successful surgical management of encapsulating peritoneal sclerosis. Perit Dial Int, 2005, 25(Suppl 4): S39-S47.
20.	Mactier RA, Sprosen TS, Gokal R, et al. Bicarbonate and bicarbonate/lactate peritoneal dialysis solutions for the treatment of infusion pain. Kidney Int, 1998, 53(4): 1061-1067.
21.	Coles GA, Gokal R, Ogg C, et al. A randomized controlled trial of a bicarbonate- and a bicarbonate/lactate-containing dialysis solution in CAPD. Perit Dial Int, 1997, 17(1): 48-51.
22.	Feriani M, Kirchgessner J, La Greca G, et al. Randomized long-term evaluation of bicarbonate-buffered CAPD solution. Kidney Int, 1998, 54(5): 1731-1738.
23.	Tranaeus A. A long-term study of a bicarbonate/lactate-based peritoneal dialysis solution-clinical benefits. The bicarbonate/lactate study group. Perit Dial Int, 2000, 20(5): 516-523.
24.	Davies SJ, Woodrow G, Donovan K, et al. Icodextrin improves the fluid status of peritoneal dialysis patients: results of a double-blind randomized controlled trial. J Am Soc Nephrol, 2003, 14(9): 2338-2344.
25.	Qi H, Xu C, Yan H, et al. Comparison of icodextrin and glucose solutions for long dwell exchange in peritoneal dialysis: a meta-analysis of randomized controlled trials. Perit Dial Int, 2011, 31(2): 179-188.
26.	Hain H, Kessel M. Aspect of new solutions for peritoneal dialysis. Nephrol Dial Transplant, 1987, 2(2): 67-72.
27.	He Q, Zhang W, Chen J. A meta-analysis of icodextrinversus glucose containing peritoneal dialysis in metabolic management of peritoneal dialysis patients. Ren Fail, 2011, 33(10): 943-948.
28.	Finkelstein F, Healy H, Abu-Alfa A, et al. Superiority of icodextrin compared with 4.25% dextrose for peritoneal ultrafiltration. J Am Soc Nephrol, 2005, 16(2): 546-554.
29.	Lin A, Qian J, Li X, et al. Icodextrin National multi-center cooperation group. Randomized controlled trial of icodextrinversus glucose containing peritoneal dialysis fluid. Clin J Am Soc Nephrol, 2009, 4(11): 1799-1804.
30.	Konings CJ, Kooman JP, Schonck M, et al. Effect of icodextrin on volume status, blood pressure and echocardiographic parameters: a randomized study. Kidney Int, 2003, 63(4): 1556-1563.
31.	Posthuma N, Ter Wee PM, Donker AJ, et al. Assessment of the effectiveness, safety, and biocompatibility of icodextrin in automated peritoneal dialysis. The Dextrin in APD in Amsterdam (DIANA) Group. Perit Dial Int, 2000, 20(2): S106-S113.
32.	Paniagua R, Orihuela O, Ventura MD, et al. Echocardiographic, electrocardiographic and blood pressure changes induced by icodextrin solution in diabetic patients on peritoneal dialysis. Kidney Int Suppl, 2008(18): S125-S130.
33.	Wolfson M, Piraino B, Hamburger RJ, et al. A randomized controlled trial to evaluate the efficacy and safety of icodextrin in peritoneal dialysis. Am J Kidney Dis, 2002, 40(5): 1055-1065.
34.	Gokal R, Mistry CD, Peers EM, et al. Peritonitis occurrence in a multicenter study of icodextrin and glucose in CAPD. MIDAS Study Group. Multicenter Investigation of Icodextrin in Ambulatory Dialysis. Perit Dial Int., 1995, 15(6): 226-230.

1. Devuyst O, Margetts PJ, Topley N. The pathophysiology of the peritoneal membrane. J Am Soc Nephrol, 2010, 21(7): 1077-1085.
2. Topley N. Membrane longevity in peritoneal dialysis: impact of infection and bio-incompatible solutions. Adv Ren Replace Ther, 1998, 5(3): 179-184.
3. Witowski J, Jörres A. Effects of peritoneal dialysis solutions on the peritoneal membrane: clinical Consequences. Perit Dial Int, 2005, 25(Suppl 3): S31-S34.
4. Pecoits-Filho R, Stenvinkel P, Heimburger O, et al. Beyond the membrane-the role of new PD solutions in enhancing global biocompatibility, Kidney Int Suppl, 2003, 2003(88): S124-S132.
5. Nau B, Schmitt CP, Almeida M, et al. BIOKID: randomized controlled trial comparing bicarbonate and lactate buffer in biocompatible peritoneal dialysis solutions in children, BMC Nephrol, 2004, 2004(5): 14.
6. Haag-Weber M, Krämer R, Haake R, et al. Low-GDP fluid (Gambrosol trio) attenuates decline of residual renal function in PD patients: a prospective randomized study. Nephrol Dial Transplant, 2010, 25(7): 2288-2296.
7. Brown F, Johnson DW. A randomized controlled trial to determine whether treatment with at neutral pH, low glucose degradation product dialysate (balance) prolongs residual renal function in peritoneal dialysis patients. Perit Dial Int, 2006, 26(1): 112-113; author reply 114.
8. Johnson DW, Brown FG, Clarke M, et al. Effects of biocompatibleversus standard fluid on peritoneal dialysis outcomes. J Am Soc Nephrol, 2012, 23(6): 1097-1107.
9. Johnson DW, Clarke M, Wilson V, et al. Rationale and design of the balANZ trial: a randomized controlled trial of low GDP, neutral pHversus standard peritoneal dialysis solution for the preservation of residual renal function, BMC Nephrol, 2010, 2010(11): 25.
10. Johnson DW, Brown FG, Clarke M, et al. The effect of low glucose degradation product, neutral pHversus standard peritoneal dialysis solutions on peritoneal membrane function: the balANZ trial. Nephrol Dial Transplant, 2012, 27(12): 4445-4453.
11. Cho Y, Johnson DW, Craig JC, et al. Biocompatible dialysis fluids for peritoneal dialysis. Cochrane Database of Systematic Reviews, 2014, 27(3): CD007554.
12. Seo EY, An SH, Cho JH, et al. Effect of biocompatible peritoneal dialysis solution on residual renal function: a systematic review of randomized controlled trials. Perit Dial Int, 2014, 34(7): 724-731.
13. Rippe B, Wieslander A, Musi B. Long-term results with low glucose degradation product content in peritoneal dialysis fluids. Contrib Nephrol, 2003(140): 47-55.
14. Choi HY, Kim DK, Lee TH, et al. The clinical usefulness of peritoneal dialysis fluids with neutral pH and low glucose degradation product concentration: an open randomized prospective trial. Perit Dial Int, 2008, 28(2): 174-182.
15. Williams JD, Topley N, Craig KJ, et al. Euro Balance Trial Group. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int, 2004, 66(1): 408-418.
16. Szeto CC, Chow KM, Lam CW, et al. Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products--a 1-year randomized control trial. Nephrol Dial Transplant, 2007, 22(2): 552-559.
17. Fried LF, Bernardini J, Johnston JR, et al. Peritonitis influences mortality in peritoneal dialysis patients. J Am Soc Nephrol, 1996, 7(10): 2176-2182.
18. Davies SJ, Bryan J, Phillips L, et al. Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis. Nephrol Dial Transplant, 1996, 11(3): 498-506.
19. Kawanishi H, Watanabe H, Moriishi M, et al. Successful surgical management of encapsulating peritoneal sclerosis. Perit Dial Int, 2005, 25(Suppl 4): S39-S47.
20. Mactier RA, Sprosen TS, Gokal R, et al. Bicarbonate and bicarbonate/lactate peritoneal dialysis solutions for the treatment of infusion pain. Kidney Int, 1998, 53(4): 1061-1067.
21. Coles GA, Gokal R, Ogg C, et al. A randomized controlled trial of a bicarbonate- and a bicarbonate/lactate-containing dialysis solution in CAPD. Perit Dial Int, 1997, 17(1): 48-51.
22. Feriani M, Kirchgessner J, La Greca G, et al. Randomized long-term evaluation of bicarbonate-buffered CAPD solution. Kidney Int, 1998, 54(5): 1731-1738.
23. Tranaeus A. A long-term study of a bicarbonate/lactate-based peritoneal dialysis solution-clinical benefits. The bicarbonate/lactate study group. Perit Dial Int, 2000, 20(5): 516-523.
24. Davies SJ, Woodrow G, Donovan K, et al. Icodextrin improves the fluid status of peritoneal dialysis patients: results of a double-blind randomized controlled trial. J Am Soc Nephrol, 2003, 14(9): 2338-2344.
25. Qi H, Xu C, Yan H, et al. Comparison of icodextrin and glucose solutions for long dwell exchange in peritoneal dialysis: a meta-analysis of randomized controlled trials. Perit Dial Int, 2011, 31(2): 179-188.
26. Hain H, Kessel M. Aspect of new solutions for peritoneal dialysis. Nephrol Dial Transplant, 1987, 2(2): 67-72.
27. He Q, Zhang W, Chen J. A meta-analysis of icodextrinversus glucose containing peritoneal dialysis in metabolic management of peritoneal dialysis patients. Ren Fail, 2011, 33(10): 943-948.
28. Finkelstein F, Healy H, Abu-Alfa A, et al. Superiority of icodextrin compared with 4.25% dextrose for peritoneal ultrafiltration. J Am Soc Nephrol, 2005, 16(2): 546-554.
29. Lin A, Qian J, Li X, et al. Icodextrin National multi-center cooperation group. Randomized controlled trial of icodextrinversus glucose containing peritoneal dialysis fluid. Clin J Am Soc Nephrol, 2009, 4(11): 1799-1804.
30. Konings CJ, Kooman JP, Schonck M, et al. Effect of icodextrin on volume status, blood pressure and echocardiographic parameters: a randomized study. Kidney Int, 2003, 63(4): 1556-1563.
31. Posthuma N, Ter Wee PM, Donker AJ, et al. Assessment of the effectiveness, safety, and biocompatibility of icodextrin in automated peritoneal dialysis. The Dextrin in APD in Amsterdam (DIANA) Group. Perit Dial Int, 2000, 20(2): S106-S113.
32. Paniagua R, Orihuela O, Ventura MD, et al. Echocardiographic, electrocardiographic and blood pressure changes induced by icodextrin solution in diabetic patients on peritoneal dialysis. Kidney Int Suppl, 2008(18): S125-S130.
33. Wolfson M, Piraino B, Hamburger RJ, et al. A randomized controlled trial to evaluate the efficacy and safety of icodextrin in peritoneal dialysis. Am J Kidney Dis, 2002, 40(5): 1055-1065.
34. Gokal R, Mistry CD, Peers EM, et al. Peritonitis occurrence in a multicenter study of icodextrin and glucose in CAPD. MIDAS Study Group. Multicenter Investigation of Icodextrin in Ambulatory Dialysis. Perit Dial Int., 1995, 15(6): 226-230.

Previous Article
帕金森病与跌倒的研究进展
Next Article
冠状动脉粥样硬化性心脏病患者过渡期管理的研究进展

West China Medical Journal

生物相容性腹膜透析液在终末期肾病中应用的进展

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content